# 21 U.S.C. 360bbb-8 Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments

21 U.S.C. 360bbb-8 Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments, “Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments”, is a U.S. Code section of [Part E—General Provisions Relating to Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb9b-72d3-b67d-4d99ebbaa239); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f06c-cd4c-73a0-842e-b15ab7e34ffb>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f06c-cb65-7672-8fda-c39517ff08c0) › [Chapter 9—Federal Food, Drug, and Cosmetic Act](https://ontology.bommaritollc.com/id/01a0f06c-cb91-72e0-858b-060e8c845f23) › [Subchapter V—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb96-7040-b454-c8f18e0e95cb) › [Part E—General Provisions Relating to Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb9b-72d3-b67d-4d99ebbaa239)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-section 21 U.S.C. 360bbb-8](https://ontology.bommaritollc.com/id/01a0f06c-cd4d-74bc-a4c3-685e3cb640e8)
- `eli:cites`:
  - [5 U.S.C. 552 Public information; agency rules, opinions, orders, records, and proceedings](https://ontology.bommaritollc.com/id/01a0edf4-5b27-7466-a019-fef93b12cea0)
  - [18 U.S.C. 202 Definitions](https://ontology.bommaritollc.com/id/01a0f06a-983a-7488-8b22-6e3ee4cb580d)
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partE-sec360bbb-8](https://ontology.bommaritollc.com/id/01a0f06c-cd4c-73a0-842e-b159b1b2e20d)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f06c-d168-773d-914c-b517c265930b)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d2-2d98-711b-a031-0830d4588906)
  - [evidence from https://www.govinfo.gov/link/uscode/21/360bbb-8?type=usc&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f15-fe3f-7724-86d4-a6551eea13c1)
- `schema:isPartOf`: [Part E—General Provisions Relating to Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb9b-72d3-b67d-4d99ebbaa239)
- `schema:legislationIdentifier`: 21 U.S.C. 360bbb-8
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code section](https://ontology.bommaritollc.com/vocab/leg/uscSection)
- `schema:name`: Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
- `schema:url`: [https://www.govinfo.gov/link/uscode/21/360bbb-8?type=usc&year=mostrecent&link-type=details](https://www.govinfo.gov/link/uscode/21/360bbb-8?type=usc&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 U.S.C. 360bbb-8 Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments

## Elsewhere

- [Official page](https://www.govinfo.gov/link/uscode/21/360bbb-8?type=usc&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partE-sec360bbb-8) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Amended by (2; `eli:amends`):
  - [Pub. L. 114-255](https://ontology.bommaritollc.com/id/01a0ee1d-96d5-7151-84b6-b5e19f0e00ec)
  - [Pub. L. 117-328](https://ontology.bommaritollc.com/id/01a0edf4-a3b3-73ad-8a5b-366dfc33cea1)
- Its changes, from (1; `eli:changes`):
  - [Pub. L. 112-144](https://ontology.bommaritollc.com/id/01a0f06a-a3b6-70e5-8204-79bb2755f506)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f06c-cd4c-73a0-842e-b15ab7e34ffb.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f06c-cd4c-73a0-842e-b15ab7e34ffb.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f06c-cd4c-73a0-842e-b15ab7e34ffb.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f06c-cd4c-73a0-842e-b15ab7e34ffb)
Cite as: 21 U.S.C. 360bbb-8 Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f06c-cd4c-73a0-842e-b15ab7e34ffb
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
